Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Immatics N.V. stock logo
IMTX
Immatics
$8.78
+2.6%		$9.09
$8.06
▼
$12.41
$1.17B1.33639,646 shs1.90 million shs
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
$1.71
+3.3%		$1.98
$0.44
▼
$3.04
$298.77M1.59461,365 shs623,684 shs
ODTX
Odyssey Therapeutics
$22.22
-1.0%		$22.64
$15.10
▼
$29.05
$1.08BN/A386,677 shs334,165 shs
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
$19.08
+4.1%		$22.12
$6.50
▼
$49.64
$1.08B1.711.28 million shs1.07 million shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Immatics N.V. stock logo
IMTX
Immatics
+2.57%+2.09%-7.87%-11.76%+3.05%
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
+3.33%-3.13%-16.83%-29.84%+242.37%
ODTX
Odyssey Therapeutics
-0.98%+7.03%-9.38%+32.26%+2,221,999,900.00%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
+4.09%-1.50%-15.12%-7.33%-60.84%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Immatics N.V. stock logo
IMTX
Immatics
$8.78
+2.6%		$9.09
$8.06
▼
$12.41
$1.17B1.33639,646 shs1.90 million shs
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
$1.71
+3.3%		$1.98
$0.44
▼
$3.04
$298.77M1.59461,365 shs623,684 shs
ODTX
Odyssey Therapeutics
$22.22
-1.0%		$22.64
$15.10
▼
$29.05
$1.08BN/A386,677 shs334,165 shs
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
$19.08
+4.1%		$22.12
$6.50
▼
$49.64
$1.08B1.711.28 million shs1.07 million shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Immatics N.V. stock logo
IMTX
Immatics
+2.57%+2.09%-7.87%-11.76%+3.05%
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
+3.33%-3.13%-16.83%-29.84%+242.37%
ODTX
Odyssey Therapeutics
-0.98%+7.03%-9.38%+32.26%+2,221,999,900.00%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
+4.09%-1.50%-15.12%-7.33%-60.84%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Immatics N.V. stock logo
IMTX
Immatics
2.63
Moderate Buy$20.60134.62% Upside
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
2.43
Hold$4.75178.59% Upside
ODTX
Odyssey Therapeutics
2.63
Moderate Buy$35.7560.89% Upside
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
2.90
Moderate Buy$41.71118.63% Upside

Current Analyst Ratings Breakdown

Latest IPSC, IMTX, VOR, and ODTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/18/2026
Immatics N.V. stock logo
IMTX
Immatics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/14/2026
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D+) ➝ Hold (C-)
8/27/2026
ODTX
Odyssey Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$44.00
8/27/2026
ODTX
Odyssey Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$44.00
8/25/2026
Immatics N.V. stock logo
IMTX
Immatics
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$17.00
8/12/2026
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$18.00 ➝ $27.00
8/11/2026
ODTX
Odyssey Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageSell (D+)
8/11/2026
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D-) ➝ Sell (D+)
8/7/2026
ODTX
Odyssey Therapeutics
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$26.00 ➝ $29.00
7/2/2026
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 10/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Immatics N.V. stock logo
IMTX
Immatics
$54.60M21.98N/AN/A$4.09 per share2.15
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
$109.16M2.83$0.01 per share124.06$1.82 per share0.94
ODTX
Odyssey Therapeutics
N/AN/AN/AN/AN/AN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Immatics N.V. stock logo
IMTX
Immatics
-$222.26M-$1.86N/AN/AN/A-495.71%-47.41%-39.45%11/17/2026 (Estimated)
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
-$9.58M-$0.93N/AN/AN/AN/A-49.51%-38.09%11/12/2026 (Estimated)
ODTX
Odyssey Therapeutics
N/A-$6.77N/AN/AN/AN/AN/AN/AN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest IPSC, IMTX, VOR, and ODTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/18/2026Q2 2026
Immatics N.V. stock logo
IMTX
Immatics
-$0.4748-$0.53-$0.0552-$0.52$12.42 million$10.44 million
8/12/2026Q2 2026
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
-$0.11-$0.17-$0.06-$0.17$2.17 millionN/A
8/11/2026Q2 2026
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
-$0.69-$0.80-$0.11-$1.16N/AN/A
8/5/2026Q2 2026
ODTX
Odyssey Therapeutics
N/A-$1.74N/A-$1.74N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Immatics N.V. stock logo
IMTX
Immatics
N/AN/AN/AN/AN/A
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
N/AN/AN/AN/AN/A
ODTX
Odyssey Therapeutics
N/AN/AN/AN/AN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Immatics N.V. stock logo
IMTX
Immatics
N/A
7.54
7.54
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
N/A
8.28
8.28
ODTX
Odyssey Therapeutics
N/A
11.36
11.36
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Immatics N.V. stock logo
IMTX
Immatics
64.41%
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
50.20%
ODTX
Odyssey Therapeutics
N/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
97.29%

Insider Ownership

CompanyInsider Ownership
Immatics N.V. stock logo
IMTX
Immatics
3.30%
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
2.40%
ODTX
Odyssey Therapeutics
N/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
0.27%
CompanyEmployeesShares OutstandingFree FloatOptionable
Immatics N.V. stock logo
IMTX
Immatics
704136.69 million132.18 millionOptionable
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
78181.07 million176.73 millionOptionable
ODTX
Odyssey Therapeutics
10048.06 millionN/AN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
7659.16 million59.00 millionN/A

Recent News About These Companies

Vor Biopharma (NASDAQ:VOR) Stock Jumps 5.3% - Here's What Happened
September 30 at 11:39 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-vor-biopharma-nasdaq-vor-stock-jumps-53-heres-what-happened-2026-09-30/
Vor Biopharma: Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
September 29 at 7:33 PM  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69706309-vor-biopharma-telitacicept-demonstrates-deep-and-durable-minimal-symptom-expression-through-48-weeks-in-generalized-myasthenia-gravis-399.htm
Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
September 29 at 12:59 PM  |  marketscreener.comM
Vor Biopharma en hausse après la publication de résultats encourageants concernant un médicament contre les maladies auto-immunes
September 29 at 12:59 PM  |  boursorama.comB
Telitacicept Demonstrates Deep and Durable Minimal Symptom  Expression Through 48 Weeks in Generalized Myasthenia Gravis
September 29 at 8:05 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/29/3370807/0/en/telitacicept-demonstrates-deep-and-durable-minimal-symptom-expression-through-48-weeks-in-generalized-myasthenia-gravis.html
Vor Biopharma (VOR) Gets a Buy from Stifel Nicolaus
September 29 at 7:59 AM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/VOR/pressreleases/4850802/vor-biopharma-vor-gets-a-buy-from-stifel-nicolaus/
Vor Biopharma Inc. (NASDAQ:VOR) Stock Rated "Moderate Buy" by Sell-Side Brokerages
September 28 at 2:44 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31056562
Vor Biopharma Inc. (NASDAQ:VOR) Stock Has Average Price Target of $41.71 According to Brokerages
September 28 at 2:43 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-vor-biopharma-inc-nasdaq-vor-stock-has-average-price-target-of-4171-according-to-brokerages-2026-09-28/
【VOR】Vor Biopharma
September 23, 2026  |  note.comN
Vor Biopharma no fórum Stifel 2026: telitacicept aposta em dupla estratégia
September 23, 2026  |  br.investing.comhttps://br.investing.com/news/transcripts/vor-biopharma-no-forum-stifel-2026-telitacicept-aposta-em-dupla-estrategia-93CH-2073344
Vor Biopharma在Stifel 2026论坛上阐述telitacicept双路径布局
September 23, 2026  |  cn.investing.comhttps://cn.investing.com/news/transcripts/article-93CH-3580464
Vor Biopharma al forum Stifel 2026: telitacicept punta su doppia strategia
September 23, 2026  |  it.investing.comhttps://it.investing.com/news/transcripts/vor-biopharma-al-forum-stifel-2026-telitacicept-punta-su-doppia-strategia-93CH-3560029
Vor Biopharma en foro Stifel 2026: telitacicept avanza en doble vía
September 23, 2026  |  mx.investing.comhttps://mx.investing.com/news/transcripts/vor-biopharma-en-foro-stifel-2026-telitacicept-avanza-en-doble-via-93CH-3774116
Vor Biopharma (NASDAQ:VOR) Shares Down 8.2% - Should You Sell?
September 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-vor-biopharma-nasdaq-vor-shares-down-82-should-you-sell-2026-09-23/
Vor Biopharma (NASDAQ:VOR) Trading Up 6.1% - Still a Buy?
September 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-vor-biopharma-nasdaq-vor-trading-up-61-still-a-buy-2026-09-22/
Vor Biopharma: A Funded Replication Story With Franchise Potential
September 18, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4947759-vor-biopharma-a-funded-replication-story-with-franchise-potential
Vor Biopharma Inc. (VOR) Stock Price, News, Quote & History - Yahoo Finance
September 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/VOR/latest-news/
Vor Biopharma Inc. (VOR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
September 9, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4944756-vor-biopharma-inc-vor-presents-at-citigroups-biopharma-back-to-school-summit-2026-transcript
Vor Biopharma (NASDAQ:VOR) Stock Price Down 5.4% - Should You Sell?
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-vor-biopharma-nasdaq-vor-stock-price-down-54-should-you-sell-2026-09-09/
97,722 Shares in Vor Biopharma Inc. $VOR Purchased by Bank of New York Mellon Corp
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-97722-shares-in-vor-biopharma-inc-vor-purchased-by-bank-of-new-york-mellon-corp-2026-09-09/
Vor Biopharma Completes Enrollment in Phase 3 Trial of Investigational Drug for Generalized Myasthenia Gravis
September 8, 2026  |  marketscreener.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Scientist handles blood sample in lab, symbolizing early cancer detection.
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
By Bridget Bennett | September 6, 2026
Split image showing a GameStop store checkout counter beside a laptop displaying the eBay website, with a graded Pokémon card nearby.
GameStop’s Comeback Case Is Getting Interesting, But eBay Still Looks Stronger
By Thomas Hughes | September 10, 2026
Dell logo illuminated in a data center setting with a laptop and server racks visible nearby.
One of Trump's Favorite Stocks Just Reported Blowout Earnings
By Jessica Mitacek | September 3, 2026
A fighter jet with open engine panels sits on an aircraft carrier deck at sunset, with the ship's superstructure visible in the background.
Defense Stocks Are Pulling Back as Their Navy Tailwinds Get Stronger
By Jeffrey Neal Johnson | September 4, 2026
A hard disk drive stands upright on a server rack in a data center aisle lined with illuminated equipment.
5 Buy-and-Hold Stocks Built to Weather a Volatile Market
By Chris Markoch | September 16, 2026
Immatics stock logo

Immatics NASDAQ:IMTX

$8.78 +0.22 (+2.57%)
Closing price 09/30/2026 04:00 PM Eastern
Extended Trading
$8.78 0.00 (-0.06%)
As of 09/30/2026 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Century Therapeutics stock logo

Century Therapeutics NASDAQ:IPSC

$1.70 +0.06 (+3.33%)
Closing price 09/30/2026 03:59 PM Eastern
Extended Trading
$1.68 -0.02 (-1.41%)
As of 09/30/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Odyssey Therapeutics NASDAQ:ODTX

$22.22 -0.22 (-0.98%)
As of 09/30/2026 04:00 PM Eastern

Odyssey Therapeutics Inc. is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines which are designed to precisely target disease pathology. Odyssey Therapeutics Inc. is based in BOSTON.

Vor Biopharma stock logo

Vor Biopharma NASDAQ:VOR

$19.08 +0.75 (+4.09%)
Closing price 09/30/2026 04:00 PM Eastern
Extended Trading
$19.07 -0.01 (-0.08%)
As of 09/30/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas